Ebola vaccine: New Russian shot targets rare Bundibugyo strain in Africa – 5 key facts

Gamaleya Center develops vaccine prototypes against Ebola that stimulate immunity, but scientists demand proof before use amid unprecedented outbreak.. 5 stations to understand the scene

Denis Logunov, Director of the Gamaleya Center in the Russian capital Moscow for Epidemiology and Microbiology Research, reported that the center has developed a new vaccine targeting the “Bundibugyo strain” causing Ebola in Africa, stimulating an immune response and providing potential protection against this deadly virus.

Logunov explained that the center developed vaccine prototypes that have demonstrated their ability to stimulate immunity and their protective efficacy in alternative tests using simplified viral variants, pointing out that these variants closely match the original virus and represent the first step toward proving the vaccine’s feasibility.

However, research is still in its early stages. Alexander Gintsburg, the center’s scientific director, acknowledged that the institute does not currently have a sample of the Bundibugyo virus to definitively test the vaccine’s efficacy. Researchers emphasize that continuing the work requires a fundamental decision regarding the necessity of the vaccine, and obtaining a sample of the pathogen currently spreading in Africa.

Scientific debate over vaccine efficacy and the need for clinical trials

In response, international scientists urge extreme caution, stressing the need for large-scale clinical trials before approving any Russian vaccine against Bundibugyo. Moses Masika, a Kenyan virologist, explained that international licensing requires more than just genetic similarity, and needs rigorous data on efficacy and safety through Phase III trials.

On his part, Andrei Prodeus, chief allergist and immunologist for children at the Moscow Region Ministry of Health, explained the mechanism for proving the new vaccine’s efficacy, where an artificial model is created using a substitute virus manufactured in the laboratory. He pointed out that the new vaccine is based on a well-known vector whose safety has been previously verified, which may allow for rapid clinical trials without the need to repeat full safety tests.

International agencies estimate that developing a specialized vaccine for Bundibugyo could take between seven to nine months, while affected communities in the Democratic Republic of Congo demand answers about why this disease has continued to be neglected since its discovery in 2007.

Humanitarian crisis and escalating numbers in Africa

Official figures show that the Ebola outbreak from the Bundibugyo strain in eastern Democratic Republic of Congo has caused thousands of deaths and injuries, with a mortality rate reaching up to 50%.

Russia is attempting to provide aid by deploying experts and mobile laboratories, but the international community believes that testing vaccines on healthcare workers may be a first step to assess the improvement of their immunity. In the absence of an approved vaccine, public health experts describe “community surveillance” as the first available vaccine to confront the virus.

5 key facts to understand the hopes and challenges of the Russian vaccine

1- Prototypes have proven laboratory efficacy: Alternative tests using simplified viral variants have shown the vaccine’s ability to stimulate immunity, but they do not replace trials on live virus samples.

2- Clinical trials may take 7-9 months: According to international agency estimates, the vaccine needs Phase III trials before official approval, which may take about a year.

3- Mortality rate reaches up to 50% in Africa: The Bundibugyo strain outbreak in the Democratic Republic of Congo has resulted in thousands of deaths and injuries, increasing the urgency for effective solutions.

4- Three international entities are preparing their own trials: Moderna, Oxford University, and IAVI are working on developing their own vaccines against Bundibugyo, creating a scientific race to save lives.

5- The final decision lies with Africa: The future of the Russian vaccine depends on African countries agreeing to provide the center with the required samples and demonstrating genuine interest in scientific collaboration.

New Russian vaccine promises strong protection against mutated #Ebola #Lebanon https://t.co/FFJN901J3j pic.twitter.com/a2IOo7b8Sa

— international events (@internatio79191) July 27, 2026

What do these developments mean?

Russian statements indicate scientific progress in confronting a deadly viral strain, but international warnings confirm that the road is long before a safe and effective vaccine is approved.

While three international entities – Moderna, Oxford University, and IAVI – are preparing for their clinical trials, the most important question remains: Will the Russian prototypes succeed in overcoming regulatory and field trial obstacles?

The biggest challenge remains obtaining the original virus sample from Africa to conduct definitive tests, in addition to regulatory decisions that will determine the fate of this vaccine in the face of an outbreak threatening thousands of lives.

Read also:

Ebola crisis in Congo: 1,309 deaths.. record spread and medical strike